Shares of Galapagos NV (GLPG) are set to open sharply lower in pre-market trading on Thursday, plunging 13.49% following the release of the company's disappointing second-quarter and first-half 2025 financial results. The biotechnology firm reported significant losses that fell well short of analyst expectations, raising concerns about its financial health and future prospects.
Galapagos posted a quarterly adjusted loss of €1.60 per share for the quarter ended June 30, a dramatic reversal from the €0.14 earnings per share reported in the same quarter last year. This result significantly missed the mean expectation of six analysts, who had forecast a loss of €0.20 per share. Adding to the disappointment, revenue declined by 16.2% to €65.29 million, falling short of the €70.60 million analysts had anticipated.
The company's financial struggles were further highlighted in its half-year results, with Galapagos reporting a loss of €3.93 per diluted share for the first six months of 2025, compared to a profit of €1.51 per share in the same period last year. Despite these challenges, half-year revenue remained unchanged at €140.3 million. The stark reversal in profitability and the revenue decline in Q2 have raised serious concerns about the company's near-term prospects, leading to the sharp sell-off in pre-market trading.
Comments